# Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

> **NCT02366195** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 112 (actual)

## Conditions studied

- Unresected Stage IIIb to IVM1c Melanoma

## Interventions

- **DRUG:** Talimogene Laherparepvec

## Key facts

- **NCT ID:** NCT02366195
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-07
- **Primary completion:** 2017-06-26
- **Final completion:** 2020-12-25
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02366195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02366195, "Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02366195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*